Physician profile
Tammy Kruger
NPI 1184135766
$3,096.95
in general payments reported to CMS, 2019-2025
34 companies · $854 in 2025
The $854 reported for 2025 was more than what 82% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $530 · 2022: $759 · 2023: $801 · 2024: $152 · 2025: $854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,750 · Education: $58.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,749.57 |
| Education | $58.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $303.97 | 2023-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Sk Life Science, INC. | $266.12 | 2021-2025 | |
| Ucb, INC. | $237.51 | 2021-2023 | Briviact, Nayzilam |
| Sumitomo Pharma America, INC. | $196.76 | 2023 | Gemtesa, Aptiom |
| Abbvie INC. | $193.32 | 2021-2023 | |
| Dexcom, INC. | $175.97 | 2021-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Lundbeck LLC | $175.71 | 2023-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $144.26 | 2022-2023 | Verquvo, Lagevrio |
| Otsuka America Pharmaceutical, INC. | $129.36 | 2022-2025 | Rexulti, Nuedexta |
| Urovant Sciences INC | $124.99 | 2022 | |
| Neurocrine Biosciences, INC. | $101.97 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.61 | 2021-2024 | Xifaxan |
| Vanda Pharmaceuticals INC. | $88.57 | 2021-2024 | Fanapt, Hetlioz |
| Lilly USA, LLC | $84.43 | 2023-2025 | Trulicity, Mounjaro |
| Amgen INC. | $79.56 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $75.08 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $74.82 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $68.75 | 2022-2024 | Farxiga |
| Paratek Pharmaceuticals, INC. | $58.98 | 2021 | |
| Novartis Pharmaceuticals Corporation | $49.81 | 2021-2023 | |
| Novo Nordisk INC | $48.63 | 2022-2023 | Rybelsus |
| Sunovion Pharmaceuticals INC. | $45.75 | 2022 | |
| Mannkind Corporation | $38.24 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.36 | 2021-2025 | Caplyta |
| Actelion Pharmaceuticals US, INC. | $33.73 | 2023-2024 | Uptravi, Opsumit |
| Boston Scientific Corporation | $28.63 | 2025 | Watchman Access System |
| Glaxosmithkline, LLC. | $28.15 | 2022-2025 | Shingrix |
| Phathom Pharmaceuticals, INC. | $21.45 | 2024-2025 | Voquezna |
| Abbott Laboratories | $17.63 | 2022 | |
| Astellas Pharma US INC | $17.16 | 2022 | |
| Amarin Pharma, INC. | $17.02 | 2021 | |
| Vivus LLC | $15.47 | 2023 | Qsymia |
| Avanir Pharmaceuticals, INC. | $15.15 | 2022 | |
| Organogenesis INC. | $15.03 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tammy Kruger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.